Healthcare / BiotechnologyShanghai
$15.79
+0.35 (+2.27%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-99.5M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
32/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.1B
P/E
175.4x
↑EV/EBITDA
13.8x
↑ROE
0.8%
↑Gross Margin
78.7%
↑Debt/Equity
0.27
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-8.3%
FCF CAGR
—
FCF margin
-7.1%
FCF / Net income
-2.48x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $640.2M · net income $18.2M · FCF $-45.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $640.2M | $640.2M | $705.1M | $784.3M | $829.1M |
| Net Income | $18.2M | $18.2M | $174.4M | $254.5M | $277.8M |
| EBITDA | $219.3M | $219.3M | $270.7M | $355.8M | $355.4M |
| EPS | 0.09 | 0.09 | 0.88 | 1.30 | 1.43 |
| Gross Margin | 78.7% | 78.7% | 80.1% | 82.7% | 84.4% |
| Operating Margin | 19.4% | 19.4% | 19.8% | 28.9% | 32.2% |
| Net Margin | 2.8% | 2.8% | 24.7% | 32.4% | 33.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.27 | 0.27 | 0.26 | 0.34 | 0.37 |
| Current Ratio | 3.13 | 3.13 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-45.1M | $-45.1M | $-292.1M | $-99.5M | $158.7M |
| Returns | |||||
| ROE | 0.8% | 0.8% | 7.6% | 11.7% | 14.6% |
| Valuation | |||||
| P/E | 175.44 | 175.44 | 22.85 | 23.75 | 29.22 |
| EV/EBITDA | 13.80 | 13.80 | 13.74 | 14.86 | 20.54 |
| P/B | 1.41 | 1.41 | 1.74 | 2.78 | 4.26 |
| Growth & Yield | |||||
| Revenue Growth | -9.2% | -9.2% | -10.1% | -5.4% | — |
| EPS Growth | -89.8% | -89.8% | -32.3% | -9.1% | — |
| Dividend Yield | 1.7% | 1.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
149.7%
EPS terminal req.
$1.40
Spread vs growth
-239.5%
5Y implied EPS CAGR
79.9%
EPS terminal req.
$1.70
Spread vs growth
-169.7%
10Y implied EPS CAGR
40.7%
EPS terminal req.
$2.73
Spread vs growth
-130.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-23.9%
Start / end P/E
24.1x → 175.4x
EPS bridge
0.88 → 0.09
Residual
-563.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.